AltPep CEO and founder Valerie Daggett. (AltPep Photo) Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai. The early data suggest that the treatment, called lecanemab, eases cognitive decline. The findings also rejuvenated hope in a therapeutic approach targeting…
